GB0921210D0 - Novel heterocyclic derivatives - Google Patents
Novel heterocyclic derivativesInfo
- Publication number
- GB0921210D0 GB0921210D0 GBGB0921210.1A GB0921210A GB0921210D0 GB 0921210 D0 GB0921210 D0 GB 0921210D0 GB 0921210 A GB0921210 A GB 0921210A GB 0921210 D0 GB0921210 D0 GB 0921210D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- heterocyclic derivatives
- novel heterocyclic
- novel
- derivatives
- heterocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000623 heterocyclic group Chemical group 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12030308P | 2008-12-05 | 2008-12-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0921210D0 true GB0921210D0 (en) | 2010-01-20 |
GB2465890A GB2465890A (en) | 2010-06-09 |
Family
ID=41641888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0921210A Withdrawn GB2465890A (en) | 2008-12-05 | 2009-12-03 | 2-Arylazole derivatives as antiprotozoal agents |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2465890A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102020587A (en) * | 2010-11-25 | 2011-04-20 | 大连凯飞精细化工有限公司 | Method for synthesizing 2-methoxy-4-cyano benzaldehyde |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102875474A (en) * | 2012-10-23 | 2013-01-16 | 中国科学院广州生物医药与健康研究院 | Novel naphthenic amine compound for heteromorphosis-resistant influenza viruses |
EP2922821B1 (en) | 2012-11-20 | 2019-07-31 | Biogen MA Inc. | S1p and/or atx modulating agents |
EP3476389A1 (en) * | 2017-10-31 | 2019-05-01 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Adamantane or bicyclic monoterpenoid derivatives for use in the treatment of leishmaniasis |
WO2024026359A1 (en) * | 2022-07-26 | 2024-02-01 | The Board Of Trustees Of The University Of Illinois | Compounds and methods for the treatment of diseases associated with parasitic worms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5430167A (en) * | 1977-08-11 | 1979-03-06 | Mitsubishi Chem Ind Ltd | 4-aminomethyl-2-phenyloxazoles and their pharmaceutically acceptable acid salts |
WO1989008652A1 (en) * | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
US5925656A (en) * | 1995-04-10 | 1999-07-20 | Dr. Reddy's Research Foundation | Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
JPH1017569A (en) * | 1996-07-05 | 1998-01-20 | Yamanouchi Pharmaceut Co Ltd | Medicine containing substituted thiazole derivative as active ingredient and new compound |
JP3634328B2 (en) * | 2001-08-10 | 2005-03-30 | 山之内製薬株式会社 | Pharmaceutical composition comprising a condensed imidazolium derivative |
ES2483992T3 (en) * | 2005-11-15 | 2014-08-08 | Otsuka Pharmaceutical Co., Ltd. | Oxazole compound and pharmaceutical composition |
-
2009
- 2009-12-03 GB GB0921210A patent/GB2465890A/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102020587A (en) * | 2010-11-25 | 2011-04-20 | 大连凯飞精细化工有限公司 | Method for synthesizing 2-methoxy-4-cyano benzaldehyde |
Also Published As
Publication number | Publication date |
---|---|
GB2465890A (en) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256310A1 (en) | N-sulphonylpyrrole derivatives | |
HK1148283A1 (en) | Heterocyclic derivatives | |
ZA201006511B (en) | Heterocyclic compound | |
IL210548A0 (en) | Spiroaminodihydrothiazine derivatives | |
EP2269990A4 (en) | Heterocyclic compound | |
EP2376494A4 (en) | Dihydropyrimidopyrimidine derivatives | |
PT2308877E (en) | Imidazopyridin-2-one derivatives | |
SG10201506608RA (en) | 3-deazaneplanocin derivatives | |
IL210406A0 (en) | Pyrrolopyridinylpyrimidin - 2 - ylamine derivatives | |
EP2291078A4 (en) | Oxazolobenzimidazole derivatives | |
EP2279532A4 (en) | Oxazolobenzimidazole derivatives | |
IL210869A0 (en) | Imidazothiadiazoles derivatives | |
IL208336A0 (en) | Pyrisazinone derivatives | |
IL210613A0 (en) | Novel acylaminobenzamide derivatives | |
EP2295406A4 (en) | Heterocyclic compound | |
ZA201005382B (en) | Substituted heteroarylamide diazepinopyrimidone derivatives | |
IL210164A0 (en) | Thiazolylpiperidine derivatives | |
ZA201005381B (en) | Substituted heteroarylamide oxazepinopyrimidone derivatives | |
HRP20150932T1 (en) | Heterocyclic compounds | |
ZA201105050B (en) | Quinazolinamide derivatives | |
ZA201008052B (en) | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | |
ZA201002580B (en) | Heterocyclic derivatives | |
EP2292613A4 (en) | Dihydroindolinone derivatives | |
GB0921210D0 (en) | Novel heterocyclic derivatives | |
IL213051A0 (en) | Difluorophenyldiacylhydrazide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |